Scientists had been waiting for more details about the two entstowwe, even though they already are being used in many countries, and one recently won the backing of the Wêreld-Gesondheidsorganisasie vir noodgebruik.
Die verslag, published online in the Journal of the American Medical Association, concluded the two entstowwe are about 73% en 78% effektief, as Sinopharm has previously claimed.
Researchers from Sinopharm and its local partners in the Middle East say the trial involved around 40,380 participants with the company’s two entstowwe — one developed by the Wuhan Institute of Biological Products and the other by the Beijing Institute of Biological Products — and a placebo. The trial was carried out in four countries — Bahrain, the United Arab Emirates, Egypt and Jordan. Egter, the study provided data for just Bahrain and the UAE.